Regeneron Pharmaceuticals (REGN) vs Takeda Pharmaceutical (TAK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Regeneron Pharmaceuticals (REGN) has outperformed Takeda Pharmaceutical (TAK) over the past year, gaining 27.2% versus a gain of 27.0%. Over five years, REGN leads with a +34.1% price change compared with +30.3% for TAK. Regeneron Pharmaceuticals is the larger company by market cap ($76.40 billion vs $58.68 billion), about 1.3 times the size.
On valuation, Regeneron Pharmaceuticals trades at a lower forward P/E (12.1x vs 34.7x for Takeda Pharmaceutical). Takeda Pharmaceutical offers the higher dividend yield (1088.73% vs 0.49%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | REGN | TAK |
|---|---|---|
| Share price | $742.12 | $18.37 |
| Market cap | $76.40B | $58.68B |
| 1-day change | +0.46% | +1.49% |
| YTD return | -3.85% | +17.83% |
| 1-year return | +27.24% | +27.04% |
| 5-year return | +34.14% | +30.28% |
| P/E ratio (TTM) | 18.27 | — |
| Forward P/E | 12.07 | 34.66 |
| EPS (TTM) | $40.63 | $-0.34 |
| Dividend yield | 0.49% | 1088.73% |
| Annual dividend | $3.64 | $200.00 |
| Revenue (latest FY) | $14.34B | — |
| Revenue growth (YoY) | +0.99% | — |
| Net income (latest FY) | $4.50B | — |
| Operating margin | 24.95% | — |
| Net margin | 31.41% | — |
| 52-week high | $859.34 | $19.10 |
| 52-week low | $541.00 | $12.99 |
| Distance from 52-week high | -13.64% | -3.82% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +15.38% | +19.54% |
| Average volume | 741.47K | 3.03M |
| Shares outstanding | 101.14M | 3.19B |
| Employees | 15,410 | 47,029 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Takeda Pharmaceutical offers a meaningfully higher dividend yield (1088.73% vs 0.49%).
- The two companies sit in different sectors: Regeneron Pharmaceuticals in Health Care and Takeda Pharmaceutical in Healthcare.
About Regeneron Pharmaceuticals
REGN stock →Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 15,410 employees
About Takeda Pharmaceutical
TAK stock →Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.
Healthcare · Drug Manufacturers - Specialty & Generic · 47,029 employees
REGN vs TAK FAQ
Which is bigger, Regeneron Pharmaceuticals or Takeda Pharmaceutical?
Regeneron Pharmaceuticals (REGN) is larger, with a market capitalization of $76.40B compared with $58.68B for Takeda Pharmaceutical (TAK).
Which stock has performed better over the past year, REGN or TAK?
REGN returned +27.24% over the past 12 months, compared with +27.04% for TAK (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Regeneron Pharmaceuticals or Takeda Pharmaceutical?
Takeda Pharmaceutical has the higher yield at 1088.73%, compared with 0.49% for Regeneron Pharmaceuticals.
Are Regeneron Pharmaceuticals and Takeda Pharmaceutical in the same industry?
No. Regeneron Pharmaceuticals is in the Health Care sector, while Takeda Pharmaceutical is in Healthcare.